An Update on Catheter-Based Renal Denervation for the Treatment of Hypertension

2021 ◽  
Vol 15 (10) ◽  
Author(s):  
Sterling A. Wheaten ◽  
Jiandong Zhang ◽  
George A. Stouffer
2020 ◽  
Vol 13 (4) ◽  
pp. 471-484 ◽  
Author(s):  
Felix Mahfoud ◽  
Jean Renkin ◽  
Horst Sievert ◽  
Stefan Bertog ◽  
Sebastian Ewen ◽  
...  

2016 ◽  
Vol 18 (1) ◽  
Author(s):  
Alexandre Persu ◽  
Sverre Kjeldsen ◽  
Jan A Staessen ◽  
Michel Azizi

2015 ◽  
Vol 17 (10) ◽  
pp. 743-750 ◽  
Author(s):  
Michael A. Weber ◽  
Ajay Kirtane ◽  
Laura Mauri ◽  
Raymond R. Townsend ◽  
David E. Kandzari ◽  
...  

2018 ◽  
Vol 94 (4) ◽  
pp. 644-646 ◽  
Author(s):  
Christina M. Wyatt ◽  
Stephen C. Textor

2021 ◽  
Author(s):  
Yu Sato ◽  
Rika Kawakami ◽  
Atsushi Sakamoto ◽  
Anne Cornelissen ◽  
Masayuki Mori ◽  
...  

Catheter-based renal denervation is a novel treatment approach for patients with hypertension and initial unblinded trials have shown promising results. The Paradise™ Ultrasound Renal Denervation System (ReCor Medical, CA, USA) is an ultrasound-based catheter with a distal balloon that acts as a coolant to protect the renal arterial wall. This device received CE-mark in 2012. Randomized, sham-controlled trials and postmarket studies have shown promising efficacy and safety results. Currently, three additional ongoing randomized, sham-controlled trials are underway in the USA, Europe, Japan and Korea, and the results will be pivotal in device approval in some of these countries. These studies with larger numbers of patients and longer duration of follow-up are needed to further confirm the safety and efficacy of this device.


Sign in / Sign up

Export Citation Format

Share Document